Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations.

Brown KE, Sin DD, Voelker H, Connett JE, Niewoehner DE, Kunisaki KM; COPD Clinical Research Network.

Respir Res. 2017 Oct 24;18(1):179. doi: 10.1186/s12931-017-0664-0.

2.

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, Clarke A, Corbelli GM, Ekong E, Emery S, Finley EB, Florence E, Infante RM, Kityo CM, Madero JS, Nixon DE, Tedaldi E, Vestbo J, Wood R, Connett JE; INSIGHT START Pulmonary Substudy Group.

Lancet Respir Med. 2016 Dec;4(12):980-989. doi: 10.1016/S2213-2600(16)30319-8. Epub 2016 Oct 20.

3.

In Regard to Valle et al.

Moghanaki D, Timmerman RD, Slatore CG, Niewoehner DE, Karas TZ.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):482-483. doi: 10.1016/j.ijrobp.2016.05.031. No abstract available.

PMID:
27598815
4.

High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.

Johnson K, McEvoy CE, Naqvi S, Wendt C, Reilkoff RA, Kunisaki KM, Wetherbee EE, Nelson D, Tirouvanziam R, Niewoehner DE.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 21;11:799-807. doi: 10.2147/COPD.S102375. eCollection 2016.

5.

Self-reported alcohol intake and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study.

Wetherbee EE, Niewoehner DE, Sisson JH, Lindberg SM, Connett JE, Kunisaki KM.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 20;10:1363-70. doi: 10.2147/COPD.S86572. eCollection 2015.

6.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

7.

Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Kunisaki KM, Niewoehner DE, Collins G, Nixon DE, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett JE; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:119-28. doi: 10.1111/hiv.12240.

8.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.

HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.

9.

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.

Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, Make B, Marchetti N, Martinez FJ, Niewoehner DE, Scanlon PD, Sciurba FC, Scharf SM, Sin DD, Voelker H, Washko GR, Woodruff PG, Lazarus SC; COPD Clinical Research Network; Canadian Institutes of Health Research.

N Engl J Med. 2014 Jun 5;370(23):2201-10. doi: 10.1056/NEJMoa1403086. Epub 2014 May 18.

10.

QVA149 versus glycopyrronium for COPD - authors' reply.

Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D.

Lancet Respir Med. 2013 Jul;1(5):e23. doi: 10.1016/S2213-2600(13)70104-8. Epub 2013 Jul 8. No abstract available.

PMID:
24429211
11.

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.

Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D.

Lancet Respir Med. 2013 May;1(3):199-209. doi: 10.1016/S2213-2600(13)70052-3. Epub 2013 Apr 23.

PMID:
24429126
12.

Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial.

Woodruff PG, Chatila W, Connett JE, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Marchetti N, Rogers TJ, Scanlon PD, Sin DD, Voelker H, Wendt C, Albert RK; COPD Clinical Research Network.

Eur Respir J. 2014 Jan;43(1):295-8. doi: 10.1183/09031936.00140613. Epub 2013 Oct 17. No abstract available.

13.

A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.

Anzueto A, Niewoehner DE, Leimer I, Rühmkorf F, Celli BR, Decramer M, Tashkin DP.

Respir Med. 2013 Dec;107(12):1912-22. doi: 10.1016/j.rmed.2013.07.020. Epub 2013 Aug 20.

14.

Severe vitamin D deficiency: a biomarker of exacerbation risk? : a reply to Heulens.

Kunisaki KM, Niewoehner DE, Connett JE.

Am J Respir Crit Care Med. 2013 Jan 15;187(2):215-6. No abstract available.

15.

Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.

Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, Connett J, Cooper JA, Criner GJ, Curtis JL, Han MK, Make B, Marchetti N, Martinez FJ, McEvoy C, Nahm MH, Niewoehner DE, Porszasz J, Reilly J, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Woodruff PG, Lazarus SC; NIH COPD Clinical Research Network.

Clin Infect Dis. 2012 Sep;55(5):e35-44. Epub 2012 May 31.

16.

A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial.

Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, Thwin SS, Huang GD, Robbins R, Sriram PS, Sharafkhaneh A, Mador MJ, Sarosi G, Panos RJ, Rastogi P, Wagner TH, Mazzuca SA, Shannon C, Colling C, Liang MH, Stoller JK, Fiore L, Niewoehner DE.

Ann Intern Med. 2012 May 15;156(10):673-83. doi: 10.7326/0003-4819-156-10-201205150-00003.

PMID:
22586006
17.

Influence of lightweight ambulatory oxygen on oxygen use and activity patterns of COPD patients receiving long-term oxygen therapy.

Casaburi R, Porszasz J, Hecht A, Tiep B, Albert RK, Anthonisen NR, Bailey WC, Connett JE, Cooper JA Jr, Criner GJ, Curtis J, Dransfield M, Lazarus SC, Make B, Martinez FJ, McEvoy C, Niewoehner DE, Reilly JJ, Scanlon P, Scharf SM, Sciurba FC, Woodruff P; COPD Clinical Research Network.

COPD. 2012 Feb;9(1):3-11. doi: 10.3109/15412555.2011.630048.

18.

Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations.

McGarvey LP, Magder S, Burkhart D, Kesten S, Liu D, Manuel RC, Niewoehner DE.

Respir Med. 2012 Apr;106(4):515-21. doi: 10.1016/j.rmed.2011.10.009. Epub 2011 Nov 18.

19.

Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study.

Kunisaki KM, Niewoehner DE, Connett JE; COPD Clinical Research Network.

Am J Respir Crit Care Med. 2012 Feb 1;185(3):286-90. doi: 10.1164/rccm.201109-1644OC. Epub 2011 Nov 10.

20.

Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.

Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.

Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29.

Supplemental Content

Loading ...
Support Center